Alirocumab (trade name Praluent) is a biopharmaceutical drug approved by the FDA on July 24, 2015, as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval.... Wikipedia

 

Manufacturer's Website: Praluent                                                                                                                                                    Average retail cost: $614/2 pens